Onward Medical has appointed Ali Kiboro as its new chief financial officer (CFO), effective immediately.

Kiboro boasts over 25 years of financial leadership experience in medical technology, tools and diagnostics, and general industry. He joins Onward from AliveDx (formerly Quotient Limited), where he served as CFO and led financial strategy, capital markets activities, and operational transformation.

Before AliveDx, Kiboro had a variety of senior finance leadership roles at Quest Diagnostics and General Motors.

“We are delighted to welcome Ali Kiboro to our leadership team,” said Dave Marver, CEO of Onward Medical. “Ali’s experience driving growth and scaling life science companies make him a strong addition to ONWARD at this important stage.”

Yesterday, the company announced that two additional individuals with spinal cord injuries (SCI) have received the company’s investigational ARC-BCI therapy. These procedures bring the total number of human implants to seven, growing the company’s leadership in developing brain-computer interface (BCI) platforms to restore thought-driven movement for people living with paralysis.

“I am excited to join Onward Medical at a time of significant momentum,” said Kiboro. “Onward’s purpose-driven mission, unique technology platforms, and fast progress across innovation and commercial fronts position the company well for the future. I look forward to contributing to its long-term success.”

In November, the company also received U.S. Food and Drug Administration (FDA) 510(k) clearance to expand the ARC-EX system’s indication for home use in the U.S.